Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

Bacterial Infection Assay Service

Online Inquiry

Background Service Workflow Advantages Case Study FAQs Why Choose Us

The urgent need for effective antibacterial strategies, particularly for immunocompromised patients post-CAR T-cell therapy, is paramount. Creative Biolabs offers a bacterial infection assay service to address the challenges of long drug development cycles and complex preclinical testing by accelerating anti-infective drug discovery, delivering precise efficacy data, and developing potent antibacterial agents through advanced microbiological techniques, robust screening platforms, and innovative infection models.

The Urgent Need for Bacterial Infection Management

The landscape of modern medicine, particularly in advanced therapies like CAR T-cell therapy, has introduced new complexities in managing patient health. Patients undergoing CAR T-cell therapy often experience significant immunosuppression, making them highly susceptible to severe bacterial infections. These infections represent a major cause of morbidity and mortality post-treatment, frequently complicating recovery and impacting overall therapeutic outcomes. Therefore, there is a critical and urgent need for robust bacterial infection management strategies to understand the baseline susceptibility of these patients, monitor for emerging resistance, and develop effective prophylactic and therapeutic antibacterial strategies specifically tailored to this vulnerable population. This is indispensable for improving patient safety and the success of innovative immunotherapies.

Fig.1 Factors Influencing Post CAR-T Infection Risk. (OA Literature) Fig.1 Risk factors for post-CAR-T infection.¹

Bacterial Infection Assay Service at Creative Biolabs

Creative Biolabs offers a comprehensive bacterial infection assay service designed to provide specific deliverables, actionable solutions, and key problem-solving capabilities tailored to your anti-infective research and development needs. We deliver precise data on compound efficacy, bacterial susceptibility, and host-pathogen dynamics, enabling informed decision-making throughout your project lifecycle. Our service follows a meticulously designed workflow, ensuring comprehensive and reliable results. Typically, the timeline for our assay ranges from 4-12 weeks, depending on the complexity of the bacterial strains, the number of compounds, and the chosen assay models.

Workflow

Step 1

Consultation & Experimental Design

This initial phase involves an in-depth discussion with our expert team to understand your specific research objectives, target pathogens, compound characteristics, and desired endpoints. We will collaboratively define the scope of your project, select the most appropriate in vitro and/or in vivo infection models, and establish a detailed experimental plan.

Step 2

Bacterial Strain Preparation & Characterization

Our microbiologists will culture and prepare your specified bacterial strains under optimal conditions. This includes verifying strain purity, assessing viability, and preparing standardized inoculums for various assays. For specific projects, we can also perform preliminary characterization of resistance profiles or virulence factors.

Step 3

Assay Execution (In Vitro & In Vivo Models)

This core stage involves the precise execution of selected bacterial infection assays.

In Vitro Assays: This may include MIC/MBC determination, time-kill kinetics, biofilm formation and eradication assays, bacterial adhesion and invasion assays, and intracellular survival assays.
In Vivo Models: We utilize a range of established animal models (e.g., murine systemic infection, pneumonia, skin infection, urinary tract infection models) to evaluate compound efficacy in a living system, assessing bacterial burden, survival rates, and pathological changes.

Step 4

Data Analysis & Interpretation

Following assay execution, our bioinformatics and microbiology specialists will meticulously process the raw data. This includes statistical analysis, normalization, and graphical representation of results. We apply rigorous analytical methods to ensure the quality.

Step 5

Comprehensive Reporting & Consultation

The final phase involves the delivery of a detailed, comprehensive report summarizing all experimental procedures, raw data, analyzed results, and their interpretation. Our team will provide an expert consultation to discuss the findings, their implications for your project, and recommend next steps for further research or development.

Our Service Advantages

Accelerated Discovery: Rapidly identify effective antibacterial compounds.
Diverse Models: Access to a wide range of in vitro and in vivo infection models.
Expert Insights: Benefit from our team's deep microbiological and pharmacological expertise.
Customizable Solutions: Tailored assays to meet your specific research needs.
Reliable Data: Generate robust and reproducible data for confident decision-making.

Case Study

Case Study One:

Through our Bacterial Infection Assay Service, a leading oncology research institute successfully identified a novel prophylactic antibiotic regimen specifically effective against common bacterial infections in CAR T-cell therapy patients, significantly reducing post-treatment complications and improving patient outcomes.

Case Study Two:

After utilizing Creative Biolabs' Bacterial Infection Assay Service, this biopharmaceutical company successfully validated the efficacy of their new antimicrobial agent against a multi-drug-resistant Pseudomonas aeruginosa strain isolated from a CAR T-cell recipient, demonstrating its potential for managing critical infections in immunocompromised patients.

FAQs

Q1: What types of bacterial strains can Creative Biolabs work with for infection assays?

A1: We have extensive experience working with a wide range of bacterial strains, including common pathogens, multi-drug resistant (MDR) strains, and fastidious organisms. We can also accommodate client-provided strains. Please discuss your specific strain requirements during the initial consultation, and we'll confirm our capabilities.

Q2: Can Creative Biolabs develop custom infection models for unique research challenges?

A2: Absolutely. While we offer a comprehensive suite of established models, our strength lies in our ability to develop and validate custom in vitro and in vivo infection models tailored to your specific research needs, including novel host-pathogen interactions or unique disease manifestations. Let's discuss your custom requirements!

Related Services

In addition to the bacterial infection assay, we also provide a series of infection assays for many other microorganisms that threaten patients after CART therapy treatment. Our services include:

Why Choose Us

Creative Biolabs is your trusted partner in advancing anti-infective research. Our bacterial infection assay service provides the critical data and insights needed to accelerate your drug discovery programs, from initial compound screening to preclinical validation. If you want to know more about this assay, please feel free to contact us.

Reference

Ahmed, Nausheen et al. "Managing Infection Complications in the Setting of Chimeric Antigen Receptor T cell (CAR-T) Therapy." Clinical hematology international vol. 6,2 31-45. 29 Apr. 2024, doi:10.46989/001c.115932. Distributed under Open Access License CC BY 4.0, without modification.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.